Predicting resistance by selection of signaling pathways

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Epidermal growth factor receptor (EGFR) mutations are found in 17% of non-small-cell lung cancer (NSCLC) patients.
• While EGFR inhibitors show initial response, low complete remission rates and eventual disease progression are common challenges.
• BIM, a pro-apoptotic protein, plays a crucial role in cellular response to EGFR inhibition.

Purpose of the Study:

• To investigate the role of BIM in mediating sensitivity to EGFR inhibitors like erlotinib.
• To explore signaling pathways (SHP2, PI3K/AKT, STAT, mTOR) involved in EGFR-mutant NSCLC response and resistance.
• To identify potential strategies for augmenting the efficacy of EGFR tyrosine kinase inhibitors (TKIs).

Main Methods:

• Analysis of BIM expression and its correlation with sensitivity to erlotinib in EGFR-mutant cell lines.
• Investigation of the involvement of SHP2, PI3K/AKT, STAT, and mTOR pathways in EGFR signaling.
• Examination of the role of stromal hepatocyte growth factor (HGF) and associated crosstalk in conferring TKI resistance.

Main Results:

• Priming BIM expression enhances sensitivity to erlotinib in EGFR-mutant cell lines.
• EGFR mutations lead to transient imbalances in survival and apoptotic signaling upon EGFR inhibition.
• Stromal HGF contributes to EGFR TKI resistance through crosstalk with integrin-b4, Eph2, CDCP1, AXL, and JAK1.

Conclusions:

• BIM expression is a critical determinant of sensitivity to EGFR inhibitors.
• Understanding the complex molecular interplay, including SHP2 and HGF-mediated resistance, is vital for improving NSCLC treatment outcomes.
• Targeted strategies modulating BIM and overcoming resistance mechanisms are needed to enhance EGFR TKI efficacy.